Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: yttrium Y 90 glass microspheres Clear all
Not listed Phase 2 Interventional

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

NCT00436267
View directory record Official record
Conditions
Metastatic Cancer, Pancreatic Cancer
Interventions
fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Phase 1 Interventional

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

NCT00846131
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib, Yttrium-90 (Y-90)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 29, 2026, 9:24 AM EDT
Active, not recruiting Not applicable Interventional

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Interventions
EYE90 Microspheres Treatment
Device
Lead sponsor
ABK Biomedical
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Tucson, Arizona • Orange, California • Altamonte Springs, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

NCT01290523
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Sep 29, 2026, 9:24 AM EDT
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Phase 2 Interventional Results available

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 29, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

NCT05953961
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Therasphere 90Y, Microwave Ablation
Device
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 29, 2026, 9:24 AM EDT
Not listed Phase 2 Interventional

Definitive Therapy for Oligometastatic Solid Malignancies

NCT01898962
View directory record Official record
Conditions
Stage IV or Recurrent Carcinoma or Sarcoma
Interventions
Complete Surgical Removal, Stereotactic Radiosurgery, Ablative external beam radiation dose, Subtotal surgical removal plus ablative radiation dose, Radioembolization
Procedure · Radiation
Lead sponsor
Rocky Mountain Cancer Centers
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
4
States / cities
Aurora, Colorado • Boulder, Colorado • Littleton, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 29, 2026, 9:24 AM EDT
Recruiting Phase 1 Interventional

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

NCT05303467
View directory record Official record
Conditions
Glioblastoma Multiforme, Recurrent Glioblastoma
Interventions
TheraSphere GBM
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

NCT01177007
View directory record Official record
Conditions
Liver Neoplasms
Interventions
TheraSphere, Yttrium-90 glass Microspheres
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Phase 1 Interventional

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

NCT01434459
View directory record Official record
Conditions
Pancreatic Neoplasms, Cholangiocarcinoma
Interventions
Gemcitabine with TheraSphere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

TheraSphere for the Treatment of Liver Metastases

NCT00511862
View directory record Official record
Conditions
Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
Interventions
Yttrium 90 glass microspheres
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Phase 1Phase 2 Interventional

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

NCT00493883
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Neoplasms
Interventions
yttrium Y 90 microspheres (TheraSphere®)
Device
Lead sponsor
Southwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Phase 1 Interventional

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 29, 2026, 9:24 AM EDT
Active, not recruiting Phase 2 Interventional

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 29, 2026, 9:24 AM EDT
Approved For Marketing No phase listed Expanded access

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

NCT01076517
View directory record Official record
Conditions
Liver Cancer
Interventions
Therasphere
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 29, 2026, 9:24 AM EDT
Completed Not applicable Interventional Results available

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

NCT01483027
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
TheraSphere
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Plasma collection
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 29, 2026, 9:24 AM EDT
Approved For Marketing No phase listed Expanded access

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

NCT00906984
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
Interventions
TheraSphere
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 29, 2026, 9:24 AM EDT
Not yet recruiting Not applicable Interventional

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

NCT07110233
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
Interventions
TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 29, 2026, 9:24 AM EDT
Completed No phase listed Observational Results available

TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.

NCT05233098
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Technetium-99m macroaggregated albumin (Tc-99m MAA)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
21 Years and older
Enrollment
6 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 29, 2026, 9:24 AM EDT
Terminated Early Phase 1 Interventional

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

NCT03812562
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Yttrium Y 90 Glass Microspheres
Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 29, 2026, 9:24 AM EDT